文献速递临床试验与 GCP流行病学与生物统计

流感疫苗接种改善急性心力衰竭患者结局(PANDA II):中国多区域、季节性、医院整群随机对照试验

Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.
PubMed 文献 · Lancet · 2025-08-30

PANDA II试验在中国12省196家医院随机分组,164家医院共纳入7771例成人急性心力衰竭患者,比较出院前免费接种流感疫苗与常规照护。疫苗接种组主要结局(12个月内全因死亡或再住院)发生率为41.2%,低于常规照护组的47.0%(OR 0.83,95%CI 0.72-0.97,p=0.019);严重不良事件发生率亦较低(52.5% vs 59.0%,OR 0.82,95%CI 0.70-0.96,p=0.013)。

要点

  • 急性心衰住院期间接种流感疫苗可降低12个月内全因死亡或再住院风险(OR 0.83)。
  • 疫苗接种组严重不良事件发生率低于常规照护组(52.5% vs 59.0%)。
  • 作者认为将流感疫苗接种整合入住院照护或可为高危患者提供广泛适用的策略。

核心结论

  • 急性心力衰竭患者住院期间接种流感疫苗可改善其生存并降低随后12个月内再住院的可能性。
  • 作者认为将流感疫苗接种整合入住院照护或可为服务不足的高危患者群体提供广泛适用的策略,该策略与资源有限及可能资源丰富的环境均相关。

研究设计与样本

  • 实用性、多区域、平行组、以医院为整群随机、对照、优效性试验,在中国三个冬季季节(2021年至2024年)开展。
  • 参与医院位于12个省的县,需具备在出院前为足够数量患者免费提供流感疫苗接种的即时服务能力。
  • 医院每年按1:1随机,按省分层,最多随机三次(即每个季节重新随机),纳入年龄≥18岁、纽约心脏协会心功能III或IV级、无流感疫苗接种禁忌证的成人心衰患者。
  • 患者入组连续三个冬季季节,从每年10月至次年3月,时间为2021年至2024年;所有患者接受常规标准照护,并在出院后1、3、6、12个月由培训过的研究人员按标准化方案随访。
  • 主要结局为12个月内全因死亡或任何再住院的复合终点,排除所有站点出院后30天内发生的事件以及中国北方站点仅夏季发生的事件。

主要发现

  • 评估252家医院合格,196家同意加入并从2021年10月起每个冬季季节初分三批随机,但32家医院随后在任何患者纳入前退出。
  • 2021年12月3日至2024年2月14日期间,164家医院每个冬季季节共纳入7771例参与者,其中3570例分配至流感疫苗接种组,4201例分配至常规照护(对照)组。
  • 主要结局在疫苗接种组3342例中发生1378例(41.2%),在常规照护组3919例中发生1843例(47.0%)(比值比0.83 [95%CI 0.72-0.97];p=0.019)。
  • 敏感性分析结果一致。
  • 发生严重不良事件的参与者数量在疫苗接种组显著低于常规照护组(1809/3444 [52.5%] vs 2426/4110 [59.0%];比值比0.82 [0.70-0.96];p=0.013)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Influenza vaccination is widely recommended to prevent death and serious illness in vulnerable people, including those with heart failure. However, the randomised evidence to support this practice is limited and few people are vaccinated in many parts of the world. We aimed to determine whether influenza vaccination can improve the outcome of patients after an episode of acute heart failure requiring admission to hospital in China. METHODS: We undertook a pragmatic, multiregional, parallel-group, cluster (hospital)-randomised, controlled, superiority trial over three winter seasons in China. Participating hospitals were located in the counties of 12 provinces with the capability of establishing a point-of-care service to provide free influenza vaccination to a sufficient number of patients before their discharge, if allocated to the intervention group. No such service was used in hospitals allocated to usual care (control) but patients were informed of fee-for-service influenza vaccination being available at local community medical centres, as per usual standard of care. Hospitals were randomised (1:1) in each year, stratified by province and up to three times (ie, new randomisation for each season), to include eligible adult (aged ≥18 years) patients with moderate to severe heart failure (New York Heart Association class III or IV) and no contraindication to influenza vaccination. Patient enrolment was conducted over three consecutive winter seasons, from October in each year to March of the following year, between 2021 and 2024. All patients received usual standard of care and were followed up at 1, 3, 6, and 12 months after their hospital discharge by trained study personnel using a standardised protocol. The primary outcome was a composite of all-cause mortality or any hospital readmission over 12 months, excluding events that occurred within 30 days after hospital discharge at all sites and in the summer season only for sites in northern China. The effect of the intervention was assessed at an individual level in the modified intention-to-treat population (all randomly assigned patients with available information until the time of last follow-up, excluding censored events) with a two-level hierarchical logistic regression model that included study period (year) as a fixed effect, and hospital and hospital-period as random effects, with the censored events excluded. The trial is registered at the Chinese Clinical Trial Registry (ChiCTR2100053264). FINDINGS: Of 252 hospitals assessed for eligibility, 196 hospitals agreed to join and were randomised in three batches at the beginning of each winter season from October, 2021, but 32 hospitals subsequently withdrew before any patients were included. Overall, 7771 participants were enrolled at 164 hospitals in each winter season between Dec 3, 2021, and Feb 14, 2024, with 3570 assigned to the influenza vaccination group and 4201 to the usual care (control) group. The primary outcome occurred in 1378 (41·2%) of 3342 patients in the vaccination group and in 1843 (47·0%) of 3919 patients in the usual care group (odds ratio 0·83 [95% CI 0·72-0·97]; p=0·019). The result was consistent in the sensitivity analysis. The number of participants with a serious adverse event was significantly lower in the vaccination group (1809 [52·5%] of 3444) than the usual care group (2426 [59·0%] of 4110; odds ratio 0·82 [0·70-0·96]; p=0·013). INTERPRETATION: Influenza vaccination during a hospital admission in patients with acute heart failure can improve their survival and reduce likelihood of readmission to hospital over the subsequent 12 months. The integration of influenza vaccination into inpatient care could offer a widely applicable strategy for an underserved high-risk patient group, that is relevant to resource-limited and possibly resource-rich settings. FUNDING: Sanofi and the Chinese Society of Cardiology.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Anderson CS, Hua C, Wang Z, et al. Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China. Lancet. 2025. PMID: 40897187. doi:10.1016/S0140-6736(25)01485-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。